Research progress on the correlation between triglyceride-glucose-body mass index and liver fibrosis in patients with Type 2 diabetes mellitus complicated with MAFLD

doi:10.3877/cma.j.issn.2095-9605.2026.02.005

Abstract

Abstract:

The prevalence of type 2 diabetes (T2DM) combined with metabolic associated fatty liver disease (MAFLD) is high. Insulin resistance (IR) serves as the link between the two. Their combined effect leads to liver cell damage, liver fibrosis, and even progression to cirrhosis. The liver fibrosis process is more obvious in T2DM patients with MAFLD. The glycerol triose phosphate glucose index (TyG), as a non-insulin-dependent, reliable, economical, and simple-to-perform new indicator for evaluating IR, combined with body mass index (BMI), can be used for screening and management of MAFLD in T2DM patients, thereby strengthening the control of risk factors and avoiding irreversible progression of the disease. This article reviews the possible mechanisms and correlations between the glycerol triose phosphate glucose index (TyG-BMI) and liver fibrosis in T2DM patients with MAFLD, with the aim of providing a basis for early assessment of liver fibrosis and early prediction and intervention of risk factors.

Key words: Triglyceride-glucose-body mass index, Type 2 diabetes, Metabolic associated fatty liver disease, Liver fibrosis

Liting Chen, Qian Xiang. Research progress on the correlation between triglyceride-glucose-body mass index and liver fibrosis in patients with Type 2 diabetes mellitus complicated with MAFLD[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2026, 12(02): 115-119.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2026.02.005

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2026/V12/I02/115

References 33

[1]	赵娅芳, 杨晋辉, 郑梦瑶, 等. 代谢相关脂肪性肝病与2型糖尿病的相关性研究进展 [J]. 胃肠病学和肝病学杂志, 2024, 33(8): 1092-1098.
[2]	曹欢易, 关海霞, 傅晓莹, 等. 内分泌疾病与非酒精性脂肪性肝病 [J]. 中国实用内科杂志, 2024, 44(01): 11-16.
[3]	龚红梅, 谭文婷, 蒋黎, 等. 2型糖尿病合并代谢相关脂肪性肝病的肝脏疾病风险评估和管理 [J]. 中华糖尿病杂志, 2025, 17(06): 773-778.
[4]	Sung S, Al-Karaghouli M, Tam M, et al. Age-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care [J]. Hepatol Commun, 2024, 9(1): e0609.
[5]	张金俊, 吕梦, 陈浩, 等. 我国成人非酒精性脂肪性肝病患病率的meta分析 [J]. 职业与健康, 2023, 39(21): 3000-3003+3010.
[6]	Eslam M, Fan JG, Yu ML, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease [J]. Hepatol Int, 2025, 19(2): 261-301.
[7]	程雅欣, 李佳. 非酒精性脂肪性肝病与常见内分泌代谢性疾病的关系及临床治疗综述 [J]. 解放军医学院学报, 2021, 42(9): 963-969.
[8]	陈兆斌, 黄丽媛, 王炳元, 等. 代谢相关脂肪性肝病与2型糖尿病的关系及共病机制研究进展 [J]. 临床肝胆病杂志, 2023, 39(10): 2454-2459.
[9]	Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease [J]. Metabolism, 2021, 123: 154868.
[10]	中华医学会内分泌学分会,中华医学会糖尿病学分会. 中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识 [J]. 中华内分泌代谢杂志, 2021, 37(7): 589-598.
[11]	Man S, Deng Y, Ma Y, et al. Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China [J]. Gastroenterology, 2023, 165(4): 1025-1040.
[12]	Park HM, Lee HS, Lee YJ, et al. The triglyceride-glucose index is a more powerful surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the homeostatic model assessment of insulin resistance [J]. Diabetes Res Clin Pract, 2021, 180: 109042-109042.
[13]	刘正一, 庄颖洁, 董旭, 等. 非酒精性脂肪性肝病肝纤维化无创诊断模型构建 [J]. 临床军医杂志, 2024, 52(7): 688-691.
[14]	李梦婷, 陆璧, 张彦, 等. 基于胰岛素抵抗替代指标评估非肥胖2型糖尿病患者NAFLD的价值 [J]. 海军医学杂志, 2024, 45(7): 739-744.
[15]	Wang X, Han X, Liu J, et al. The association of TyG-BMI with MAFLD and liver fibrosis: a cross-sectional study [J]. Sci Rep, 2026, 16(1): 10590.
[16]	Wu X, Mo J, Yu J, et al. The relationship between triglyceride-glucose index, triglyceride-glucose-body mass index, and the severity of hepatic steatosis and liver fibrosis in patients with MASLD: a cross-sectional study [J]. Front Nutr, 2026, 13: 1740308.
[17]	Zhang F, Han Y, Wu Y, et al. Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease [J]. Ann Med, 2024, 56(1): 2409342.
[18]	徐乐灿. TyG-BMI指数与T2DM合并MASLD患者肝纤维化风险严重程度的相关性分析:一项多中心横断面研究 [D]. 南昌: 南昌大学, 2025: 16-17.
[19]	杨燕, 姚艺璇, 洪秀韬, 等. 应用胰岛素抵抗替代指标评估2型糖尿病患者非酒精性脂肪肝及进展性肝纤维化的价值 [J]. 中华内分泌代谢杂志, 2021, 37(4): 281-287.
[20]	叶圣莹, 秦燕. 糖尿病致肝损伤机制的研究进展 [J]. 肝脏, 2023, 28(6): 737-739.
[21]	蔡魏, 徐积兄, 邱剑, 等. 食源性晚期糖基化终末产物对小鼠非酒精性脂肪肝病的影响 [J]. 当代医学, 2022, 28(31): 1-6.
[22]	Tuleta I, Frangogiannis NG. Diabetic fibrosis [J]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(4): 166044.
[23]	梁秀睿, 闪雪纯, 关晶, 等. 高血糖诱导肝星状细胞5-羟色胺降解在2型糖尿病致肝脏炎症和纤维化时的作用 [J]. 北京大学学报（医学版）, 2022, 54(6): 1141-1150.
[24]	高云龙, 吴雄健. 代谢性疾病驱动下的非酒精性脂肪性肝病 [J]. 赣南医学院学报, 2022, 42(7): 758-764.
[25]	Zhang F, Han Y, Wu Y, et al. Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease [J]. Ann Med, 2024, 56(1): 2409342.
[26]	Li H, Meng Y, He S, et al. Macrophages, Chronic Inflammation, and Insulin Resistance [J]. Cells, 2022, 11(19): 3001.
[27]	Niu X, Nong S, Gong J, et al. Research on promoting liver fibrosis injury by the targeted regulation of miR-202 for HGF to activate HSC [J]. Ir J Med Sci, 2020, 189(4): 1295-1304.
[28]	Hu MJ, Long M, Dai RJ, et al. Acetylation of H3K27 activated incRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3 [J]. Mol Cell Biochem, 2022, 477(1): 191-203.
[29]	郑烽锋, 邱荣仙, 胡震霆, 等. 代谢相关性脂肪性肝病患者发生明显肝纤维化的相关因素研究 [J]. 中国卫生标准管理, 2023, 14(19): 120-123.
[30]	张彦康, 张婷, 邱瑾, 等. 脂肪衰老与代谢紊乱 [J]. 中国科学（生命科学）, 2024, 54(5): 789-804.
[31]	李玟, 木胡牙提. 健康体检人群TyG指数、TyG-BMI与心血管疾病高风险的关系研究 [J]. 新疆医科大学学报, 2025, 48(1): 15-22.
[32]	罗萍萍, 刘群, 黄丽雯, 等. 甘油三酯葡萄糖体质量指数（TyG-BMI）对高脂血症性急性胰腺炎严重程度的预测价值 [J]. 临床肝胆病杂志, 2024, 40(8): 1661-1665.
[33]	郭丰硕, 李美艺, 张子腾, 等. 老年骨质疏松风险预测新标杆—TyG-BMI的诊断潜力 [J].中国实验诊断学, 2025, 29(1): 51-55.

Please choose a citation manager

Content to export